RLL receives approval to commercialize Furosemide tablets

39737 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

RLL receives approval to commercialize Furosemide tablets

Ranbaxy receives approval to commercialize Furosemide tablets in the US

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Ipca Laboratories lifts up on alliance with Ranbaxy Stocks in news: Ranbaxy, Welspun Guj, Zee Tele, Bajaj Auto Ranbaxy in-licenses NDDS cardiovascular drug Ranbaxy can touch Rs 444 in short term ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 25/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Furosemide Tablets USP, 20 mg, 40 mg, and 80 mg.  The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Lasix® Tablets, 20 mg, 40 mg, and 80 mg, respectively, of Aventis Pharmaceuticals Inc.  Total annual market sales for Furosemide Tablets were $70 million (IMS - MAT: June 2006).

Furosemide is indicated in adults, infants, and children for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.  Furosemide is particularly useful when an agent with greater diuretic potential is desired.   Also, Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.

"This approval represents an opportunity for RPI to introduce another affordable generic alternative and further increase our ever-growing product portfolio to meet the needs of our customers as well as patients and prescribers in the U.S. healthcare system.  This approval is the result a strategic alliance with Ipca Laboratories Ltd. of Mumbai, India, who will develop a number of generic prescription pharmaceutical products which will be marketed by RPI in the U.S in the future, following US FDA approval.,"  according to Jim Meehan, Vice President, U.S. Sales and Marketing for RPI.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company.  RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Contd on page 2...